EC approves Bavarian Nordic's smallpox vaccine

The European Commission approved an MAA from Bavarian Nordic A/S (CSE:BAVA) for its Imvanex smallpox vaccine. The third-generation modified vaccinia Ankara (MVA) virus vaccine is approved for active immunization against smallpox disease for the general adult population, including those with weakened immune systems. The vaccine is in Phase III testing in the U.S., where Bavarian Nordic has been supplying it under the name Imvamune to the U.S. Strategic National Stockpile for emergency use since 2010. ...